Therapeutically, OX1R-selective agonists hold promise for β-cell rescue and hypoglycemia countermeasures, while timed DORAs, such as suvorexant, offer a novel approach to nocturnal hepatic insulin resistance in type 2 diabetes. This evidence concerns the gene INS and Hypoglycemia.